Gerresheimer Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Gerresheimer ha aumentado sus beneficios a una tasa media anual de 13.4%, mientras que los beneficios de la industria de Life Sciences han experimentado un crecimiento de 13.9% anual. Los ingresos han ido creciendo a una tasa media de 9.6% al año. La rentabilidad financiera de Gerresheimer es de 8%, y sus márgenes netos son de 5.7%.
Información clave
13.4%
Tasa de crecimiento de los beneficios
11.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Life Sciences | 26.8% |
| Tasa de crecimiento de los ingresos | 9.6% |
| Rentabilidad financiera | 8.0% |
| Margen neto | 5.7% |
| Próxima actualización de resultados | 26 Feb 2025 |
Actualizaciones de resultados anteriores recientes
Recent updates
Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
Oct 03
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Sep 29Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
Aug 31Shareholders Will Most Likely Find Gerresheimer AG's (ETR:GXI) CEO Compensation Acceptable
May 30Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
May 22An Intrinsic Calculation For Gerresheimer AG (ETR:GXI) Suggests It's 40% Undervalued
May 03Analysts Are Updating Their Gerresheimer AG (ETR:GXI) Estimates After Its First-Quarter Results
Apr 14Gerresheimer's (ETR:GXI) Dividend Will Be €1.25
Apr 12Gerresheimer (ETR:GXI) Has A Somewhat Strained Balance Sheet
Apr 10Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
Feb 25Investors Still Waiting For A Pull Back In Gerresheimer AG (ETR:GXI)
Feb 10At €92.85, Is Gerresheimer AG (ETR:GXI) Worth Looking At Closely?
Jan 23Are Investors Undervaluing Gerresheimer AG (ETR:GXI) By 28%?
Jan 03Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Dec 15When Should You Buy Gerresheimer AG (ETR:GXI)?
Oct 19An Intrinsic Calculation For Gerresheimer AG (ETR:GXI) Suggests It's 42% Undervalued
Oct 01Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Aug 26Should You Investigate Gerresheimer AG (ETR:GXI) At €105?
Jul 06Gerresheimer AG's (ETR:GXI) Intrinsic Value Is Potentially 94% Above Its Share Price
Jun 18Gerresheimer (ETR:GXI) Is Paying Out A Dividend Of €1.25
Apr 05Is Gerresheimer (ETR:GXI) A Risky Investment?
Mar 17Gerresheimer's (ETR:GXI) Dividend Will Be €1.25
Feb 27What Does Gerresheimer AG's (ETR:GXI) Share Price Indicate?
Feb 15Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Nov 18Is Now An Opportune Moment To Examine Gerresheimer AG (ETR:GXI)?
Sep 06Is Gerresheimer (ETR:GXI) A Risky Investment?
Aug 18Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
May 31Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
May 16Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
May 02Gerresheimer (ETR:GXI) Has Affirmed Its Dividend Of €1.25
Apr 18Gerresheimer (ETR:GXI) Has Affirmed Its Dividend Of €1.25
Apr 04Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Mar 21Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Mar 06Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Feb 20At €72.85, Is Gerresheimer AG (ETR:GXI) Worth Looking At Closely?
Feb 17Is Gerresheimer (ETR:GXI) A Risky Investment?
Jan 06What Does Gerresheimer AG's (ETR:GXI) Share Price Indicate?
Nov 04Does Gerresheimer (ETR:GXI) Have A Healthy Balance Sheet?
Sep 23Is Gerresheimer AG (ETR:GXI) Trading At A 24% Discount?
Sep 05Should You Think About Buying Gerresheimer AG (ETR:GXI) Now?
Jul 11Is Gerresheimer (ETR:GXI) A Risky Investment?
Jun 24Desglose de ingresos y gastos
Cómo gana y gasta dinero Gerresheimer. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Aug 24 | 2,012 | 114 | 368 | 19 |
| 31 May 24 | 2,002 | 115 | 368 | 15 |
| 29 Feb 24 | 1,999 | 117 | 372 | 13 |
| 30 Nov 23 | 1,990 | 116 | 373 | 16 |
| 31 Aug 23 | 1,974 | 107 | 380 | 19 |
| 31 May 23 | 1,959 | 107 | 378 | 23 |
| 28 Feb 23 | 1,904 | 97 | 368 | 26 |
| 30 Nov 22 | 1,817 | 96 | 351 | 22 |
| 31 Aug 22 | 1,725 | 91 | 336 | 17 |
| 31 May 22 | 1,634 | 82 | 314 | 15 |
| 28 Feb 22 | 1,566 | 85 | 298 | 12 |
| 30 Nov 21 | 1,498 | 84 | 285 | 10 |
| 31 Aug 21 | 1,465 | 86 | 278 | 8 |
| 31 May 21 | 1,432 | 93 | 272 | 8 |
| 28 Feb 21 | 1,418 | 94 | 272 | 9 |
| 30 Nov 20 | 1,419 | 89 | 275 | 8 |
| 31 Aug 20 | 1,385 | -25 | 275 | 7 |
| 31 May 20 | 1,394 | -32 | 275 | 5 |
| 29 Feb 20 | 1,388 | -14 | 273 | 1 |
| 30 Nov 19 | 1,392 | 81 | 273 | 0 |
| 31 Aug 19 | 1,415 | 207 | 273 | 0 |
| 31 May 19 | 1,410 | 207 | 270 | 0 |
| 28 Feb 19 | 1,386 | 179 | 265 | 0 |
| 30 Nov 18 | 1,368 | 129 | 259 | 0 |
| 31 Aug 18 | 1,351 | 124 | 258 | 0 |
| 31 May 18 | 1,329 | 131 | 256 | 0 |
| 28 Feb 18 | 1,336 | 137 | 258 | 0 |
| 30 Nov 17 | 1,348 | 101 | 259 | 0 |
| 31 Aug 17 | 1,331 | 49 | 257 | 0 |
| 31 May 17 | 1,350 | 53 | 259 | 0 |
| 28 Feb 17 | 1,358 | 56 | 258 | 0 |
| 30 Nov 16 | 1,375 | 58 | 259 | 0 |
| 31 Aug 16 | 1,299 | 118 | 243 | 0 |
| 31 May 16 | 1,292 | 106 | 240 | 0 |
| 29 Feb 16 | 1,301 | 99 | 238 | 0 |
| 30 Nov 15 | 1,283 | 96 | 231 | 0 |
| 31 Aug 15 | 1,335 | 69 | 236 | 0 |
| 31 May 15 | 1,315 | 69 | 235 | 0 |
| 28 Feb 15 | 1,294 | 68 | 230 | 0 |
| 30 Nov 14 | 1,290 | 66 | 228 | 0 |
| 31 Aug 14 | 1,282 | 71 | 235 | 0 |
| 31 May 14 | 1,275 | 71 | 231 | 0 |
| 28 Feb 14 | 1,267 | 63 | 235 | 0 |
| 30 Nov 13 | 1,266 | 62 | 237 | 0 |
Ingresos de calidad: GXI tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (5.7%) de GXI son superiores a los del año pasado (5.4%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de GXI han crecido un 13.4% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de GXI en el último año (6.4%) está por debajo de su media de 5 años (13.4% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de GXI en el último año (6.4%) superó al de la industria Life Sciences 5.4%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de GXI (8%) se considera baja.